March 4, 2025: PRIM-ER Team Develops Innovative Statistical Techniques for Stepped-Wedge Trials

Cover image of Statistics in MedicineResearchers with PRIM-ER, an NIH Collaboratory Trial, published 2 innovative statistical techniques for evaluating intervention effects in stepped-wedge, cluster randomized trials. The new models, which use Bayesian methods, outperformed traditional analytic methods and other Bayesian approaches in simulations and real-world applications.

The article was published online in Statistics in Medicine.

In cluster randomized trials with stepped-wedge designs, the clusters are randomized into several groups, and all groups start the trial in the control condition. Groups of clusters cross over to the intervention condition on a staggered timeline, and all groups receive the intervention before the end of the trial.

Stepped-wedge designs can be advantageous when simultaneous rollout of the intervention to all clusters is infeasible, or when withholding the intervention from any cluster would be unethical, or when there is a risk of contamination between intervention subjects and control subjects. However, stepped-wedge designs can also introduce confounding by time, as the intervention is rolled out to clusters in waves. Temporal trends during the study can influence the study’s outcomes.

(Learn more about stepped-wedge designs in the Living Textbook.)

The PRIM-ER researchers tested 2 new Bayesian hierarchical penalized spline models to improve the estimation of intervention effects in stepped-wedge trials. The first model focuses on immediate intervention effects and accounts for large numbers of clusters and time periods. The second model extends the first by accounting for time-varying intervention effects. The researchers applied both models to data from PRIM-ER.

Read the full report.

PRIM-ER tested a multidisciplinary primary palliative care intervention in a diverse mix of emergency departments in the United States to improve the delivery of goal-directed emergency care of older adults. The study was supported by the National Institute on Aging. Learn more about PRIM-ER.

March 8, 2022: New Article Examines Ethical Considerations in Stepped-Wedge Cluster Randomized Trial Designs

Members of the NIH Pragmatic Trials Collaboratory Ethics and Regulatory Core published a new article in Contemporary Clinical Trials exploring the ethical and epistemic advantages and challenges specific to pragmatic stepped-wedge cluster randomized trial designs.

Contemporary Clinical TrialslsThe article titled “Ethical and Epistemic Issues in the Design and Conduct of Pragmatic Stepped-wedge Cluster Randomized Clinical Trials” was published online ahead of print in a special issue on pragmatic and virtual trials.

The authors draw on real-world examples from 5 NIH Collaboratory Trials: ACP PEACE, LIRE, NOHARM, PRIM-ER, and TSOS. The article examines practical, ethical, and epistemic issues faced by these NIH Collaboratory Trials.

In a traditional parallel cluster randomized trial, some clusters receive the intervention while other clusters do not, potentially depriving this control group of a beneficial intervention.  The stepped-wedge cluster randomized trial (SW-CRT) design takes steps toward minimizing this ethical dilemma by rolling out the intervention to all clusters over a predetermined time schedule.  This type of trial may have logistical and statistical advantages for researchers while allowing all study groups the opportunity to benefit from the intervention.

The unique design of SW-CRTs may also lead to regulatory challenges involving informed consent, bias due to contamination of the control clusters, or changing study conditions due to the extended length of time over which an intervention is rolled out.  The decision to conduct a pragmatic SW-CRT requires careful consideration of these challenges weighed against the possible advantages.

The NIH Pragmatic Trials Collaboratory is supported by the NIH Common Fund through a cooperative agreement from the Office of Strategic Coordination within the Office of the NIH Director, and through the NIH HEAL Initiative.